Modeling ALS in a dish: how organoids are transforming research

Area of Science:

• Neuroscience
• Stem Cell Biology
• Disease Modeling

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease with complex causes, including genetic and environmental factors.
• Current research models, like animal and 2D cell cultures, inadequately represent human-specific disease mechanisms.
• Developing effective ALS therapies is challenging due to the disease's intricate pathophysiology.

Purpose of the Study:

• To review the application of induced pluripotent stem cell (iPSC)-derived organoids in Amyotrophic Lateral Sclerosis (ALS) research.
• To highlight the potential of 3D organoid models for understanding ALS pathogenesis and facilitating drug discovery.
• To provide a comprehensive overview of differentiation protocols, experimental strategies, and key findings in ALS organoid research.

Main Methods:

• Utilizing induced pluripotent stem cell (iPSC) technology to generate patient-specific or disease-relevant cell types.
• Developing three-dimensional (3D) organoid models, including spinal and neuromuscular organoids.
• Employing organoids to recapitulate key pathological features of ALS, such as motor neuron degeneration and protein aggregation.
• Validating and benchmarking organoid models against established ALS research findings.

Main Results:

• iPSC-derived organoids successfully model critical aspects of ALS pathophysiology, including motor neuron loss and neuromuscular junction defects.
• These 3D models exhibit human-specific disease characteristics not fully captured by traditional models.
• Organoids serve as effective platforms for mechanistic studies and high-throughput drug screening for potential ALS therapeutics.
• Spinal and neuromuscular organoids bridge the gap between simplified in vitro systems and the human nervous system.

Conclusions:

• iPSC-derived organoids represent a significant advancement in ALS research, offering a more accurate and human-relevant disease model.
• These models hold immense translational potential for accelerating the development of personalized therapies for ALS.
• Further research and validation are crucial to fully harness the capabilities of organoids in clinical applications and therapeutic discovery for ALS.